Retina

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Baruch D. Kuppermann, MD, PhD, welcomes ophthalmologists to attend the upcoming Congress on Controversies in Ophthalmology in Seville, Spain.

KOLOA, Hawaii — Large language models are impacting ophthalmology in a myriad of ways, according to a speaker here.

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

The foveal avascular zone, or FAZ, area deteriorated at 12 months in eyes with stable laser-treated proliferative diabetic retinopathy and macular capillary nonperfusion, but vision loss was not common, according to a study.

NEW YORK — In this presentation from OSN New York Retina, Carl D. Regillo, MD, of Wills Eye Hospital, provides guidelines for the treatment of proliferative diabetic retinopathy.

Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic atrophy, according to a press release.

NEW YORK — In this presentation from OSN New York Retina, Ferhina S. Ali, MD, MPH, discusses how real-world experience with new anti-VEGF therapies is measuring up to what was seen in clinical trials.

Cencora completed its acquisition of Retina Consultants of America, according to a press release.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Sharon Bakalash, MD, PhD, CBA, of Astellas Ophthalmics, discusses the company’s pipeline for geographic atrophy as well as AI’s growing role in treating the condition.